丁型肝炎市場規模、佔有率和成長分析：按療法、適應症、通路、最終用戶、診斷方法和地區分類－2026-2033年產業預測

2024 年全球丁型肝炎市場價值為 3.825 億美元，預計到 2025 年將成長至 4.2503 億美元，到 2033 年將成長至 9.854 億美元，在預測期（2026-2033 年）內複合年成長率為 11.12%。

全球丁型肝炎市場正在成長，主要受乙型肝炎感染率高和人們對丁型肝炎診斷意識不斷提高的推動。抗病毒藥物研發投入的增加、肝炎篩檢計畫的擴大以及法規核准的進展，都促進了藥物銷售的成長。乙型肝炎的負擔和丁型肝炎併發症發生率的上升是影響市場擴張的關鍵因素。擴大丁型肝炎患者常規篩檢的舉措，使得患者能夠更早合格治療。此外，各國政府為根除病毒性肝炎所做的努力，也改善了診斷和治療的可近性，加速了市場成長。然而，治療費用高昂、低收入地區認知度低以及治療資源有限等挑戰，可能會阻礙市場的長期滲透。

全球丁型肝炎市場按治療方法、適應症、分銷管道、最終用戶、診斷方法和地區進行細分。依治療方法分類，市場分為聚乙二醇α干擾素、布雷維魯肽（Hepcludex）和羅那法尼（在研）。依適應症分類，市場分為慢性丁型肝炎和丁型肝炎病毒/B型肝炎病毒合併感染。依分銷管道分類，市場分為醫院藥房和專科藥房。依最終用戶分類，市場分為肝病診所和醫院。依診斷方法分類，市場分為血清學檢測和PCR檢測。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球丁型肝炎市場成長要素

全球丁型肝炎市場正受益於一系列強力的公共衛生宣傳活動而蓬勃發展，這些活動提高了公眾對丁型肝炎的認知，並推廣針對高風險族群的預防性健康策略。這些努力倡導全面的篩檢項目，從而增加了確診患者的數量，並促進了必要藥物治療的引入。醫護人員在實施主動檢測方案方面發揮著至關重要的作用，這些方案有助於早期療育，並提高診斷和治療藥物的市場滲透率。此外，這些公共衛生措施旨在改善患者的治療效果，從而增強產業信心，並刺激創新藥物解決方案的持續研發。

全球丁型肝炎市場限制因素

全球丁型肝炎市場面臨許多挑戰，阻礙了其成長潛力，尤其是在醫療資源匱乏的低收入地區。醫療基礎設施不足和診斷檢測手段匱乏導致許多患者未能診斷和治療。這種認知不足和缺乏經濟實惠的治療方案導致診斷延誤，並限制了創新療法的應用。此外，醫療系統的資金限制也阻礙了製藥公司在這些地區投資臨床試驗和推出新療法。這些因素共同導致市場萎縮，並阻礙了丁型肝炎有效治療的進展。

全球丁型肝炎市場趨勢

全球丁型肝炎市場正經歷顯著的發展趨勢，這主要得益於免疫療法的進步以及針對丁型肝炎病毒抗原的新藥研發。聯合治療的整合正在推進，旨在最佳化病毒清除效果，同時最大限度地減輕肝臟負擔。該行業正迅速推動市場發展，並借鑒了乙型和丙型肝炎治療的成功案例、創新的轉化研究以及不斷完善的疾病管理指南。患者群體日益積極地倡導採用這些新療法，並期待生活品質顯著改善。這種充滿活力的市場環境正在推動新的報銷策略和培訓舉措的實施，從而提高患者獲得尖端治療的機會。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球丁型肝炎市場規模：依治療方式分類

• 聚α干擾素
• 短尾科（Hepcledex）
• 羅那法尼（研發中）

全球丁型肝炎市場規模：依適應症分類

• 慢性下型肝炎
• HDV-HBV合併感染

全球丁型肝炎市場規模：按分銷管道分類

• 醫院藥房
• 專科藥房

全球丁型肝炎市場規模：依最終用戶分類

• 肝病診所
• 醫院

全球丁型肝炎市場規模：依診斷方式分類

• 血清學檢測
• PCR檢測

全球丁型肝炎市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Gilead Sciences
• Hepion Pharmaceuticals
• Eiger BioPharmaceuticals（Lonafarnib）
• MYR GmbH（Gilead-Hepcludex）
• Roche Diagnostics
• AbbVie Inc.
• Janssen（J&J）
• Spring Bank Pharmaceuticals
• Vir Biotechnology
• Aligos Therapeutics
• Antios Therapeutics
• Arbutus Biopharma
• Replicor Inc.
• Assembly Biosciences
• Enanta Pharmaceuticals
• Bristol Myers Squibb
• Merck & Co.
• GlaxoSmithKline
• Sanofi SA
• Boehringer Ingelheim

結論與建議

Global Hepatitis D Market size was valued at USD 382.5 Million in 2024 and is poised to grow from USD 425.03 Million in 2025 to USD 985.4 Million by 2033, growing at a CAGR of 11.12% during the forecast period (2026-2033).

The global hepatitis D market is experiencing growth driven by the high prevalence of hepatitis B infections and the rising awareness of hepatitis D diagnosis. Enhanced investments in antiviral drug development, coupled with the expansion of hepatitis screening programs and favorable regulatory approvals, are contributing to increased therapeutic sales. The burden of hepatitis B and the rising incidence of hepatitis D co-infection are significant factors influencing market expansion. Efforts to increase routine HDV screening among hepatitis B patients facilitate earlier treatment eligibility. Additionally, government initiatives aimed at eliminating viral hepatitis are improving access to diagnosis and care, fostering market advancement. However, challenges such as high treatment costs, limited awareness in lower-income regions, and restricted therapy access may hinder long-term market penetration.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hepatitis D market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hepatitis D Market Segments Analysis

Global hepatitis d market is segmented by treatment, indication, distribution channel, end-user, diagnosis, and region. Based on treatment, the market is segmented into Pegylated Interferon Alpha, Bulevirtide (Hepcludex), and Lonafarnib (Pipeline). Based on indication, the market is segmented into Chronic Hepatitis D and HDV-HBV Co-Infection. Based on distribution channel, the market is segmented into hospital pharmacies and specialty pharmacies. Based on end-user, the market is segmented into hepatology clinics and hospitals. Based on diagnosis, the market is segmented into serology testing and PCR testing. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Driver of the Global Hepatitis D Market

The global market for hepatitis D is bolstered by the surge in robust public health campaigns that heighten awareness about the disease and promote preventative health strategies among at-risk populations. These initiatives advocate for comprehensive screening programs, thereby expanding the pool of diagnosed patients and facilitating the introduction of essential pharmaceutical treatments. Healthcare professionals play a pivotal role by implementing proactive testing protocols, which foster early intervention and improve market penetration for both diagnostics and therapies. Moreover, these public health efforts are aimed at enhancing patient outcomes, thereby strengthening industry confidence and encouraging the ongoing development of innovative pharmaceutical solutions.

Restraints in the Global Hepatitis D Market

The Global Hepatitis D market faces significant challenges that hinder its growth potential, particularly in low-income areas where access to healthcare is severely limited. Poor healthcare infrastructure and a scarcity of available diagnostic tests contribute to a situation where many individuals remain undiagnosed and untreated. This lack of awareness and affordable options leads to delays in diagnosis and limits the adoption of innovative therapies. Furthermore, the financial constraints faced by healthcare systems discourage pharmaceutical companies from investing in clinical trials or introducing new treatments in these regions. This combination of factors contributes to market displacement and stifles progress in addressing Hepatitis D effectively.

Market Trends of the Global Hepatitis D Market

The global hepatitis D market is experiencing a significant trend driven by advancements in immunotherapy and the development of new agents targeting hepatitis D virus antigens. There is a growing integration of combination therapies aimed at achieving optimal viral eradication while minimizing liver intolerance. The industry is rapidly progressing towards the market by leveraging successful hepatitis B and C treatment outcomes, innovative translational research, and evolving disease management guidelines. Patient organizations are increasingly advocating for these emerging therapies, anticipating a marked improvement in quality of life. This dynamic landscape is facilitating the implementation of new reimbursement strategies and training initiatives, thereby enhancing access to cutting-edge treatments.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Hepatitis D Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Pegylated Interferon Alpha
• Bulevirtide (Hepcludex)
• Lonafarnib (Pipeline)

Global Hepatitis D Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Chronic Hepatitis D
• HDV-HBV Co-Infection

Global Hepatitis D Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies

Global Hepatitis D Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hepatology Clinics
• Hospitals

Global Hepatitis D Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Serology Testing
• PCR Testing

Global Hepatitis D Market Size & CAGR (2026-2033)

• North America (Treatment, Indication, Distribution, End-User, Diagnosis)
  • US
  • Canada
• Europe (Treatment, Indication, Distribution, End-User, Diagnosis)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Indication, Distribution, End-User, Diagnosis)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Indication, Distribution, End-User, Diagnosis)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Indication, Distribution, End-User, Diagnosis)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hepion Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eiger BioPharmaceuticals (Lonafarnib)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MYR GmbH (Gilead - Hepcludex)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen (J&J)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spring Bank Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vir Biotechnology
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aligos Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Antios Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arbutus Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Replicor Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Assembly Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enanta Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations